548 related articles for article (PubMed ID: 26960633)
21. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
[TBL] [Abstract][Full Text] [Related]
22. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.
Tapia G; Baptista MJ; Muñoz-Marmol AM; Gaafar A; Puente-Pomposo M; Garcia O; Marginet-Flinch R; Sanz C; Navarro JT; Sancho JM; Ribera JM; Ariza A; Mate JL
APMIS; 2015 Jul; 123(7):596-603. PubMed ID: 26010683
[TBL] [Abstract][Full Text] [Related]
23. Inferior survival in high-grade B-cell lymphoma with
McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
[TBL] [Abstract][Full Text] [Related]
24. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
[TBL] [Abstract][Full Text] [Related]
25. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome.
Gualco G; Weiss LM; Harrington WJ; Bacchi CE
Am J Surg Pathol; 2009 Dec; 33(12):1815-22. PubMed ID: 19816150
[TBL] [Abstract][Full Text] [Related]
26. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
27. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH
J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157
[TBL] [Abstract][Full Text] [Related]
28. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
29.
Tourneret A; Alame M; Rigau V; Bauchet L; Fabbro M; De Oliveira L; Cacheux V; Costes V; Lacheretz-Szablewski V
J Clin Pathol; 2021 Oct; 74(10):650-656. PubMed ID: 32912960
[TBL] [Abstract][Full Text] [Related]
30. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
[TBL] [Abstract][Full Text] [Related]
31. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.
Bellas C; García D; Vicente Y; Kilany L; Abraira V; Navarro B; Provencio M; Martín P
PLoS One; 2014; 9(6):e98169. PubMed ID: 24887414
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological and fluorescence in situ hibridisation analysis of primary testicular diffuse large B-cell lymphoma: a single-centre case series.
Jovanovic MP; Mihaljevic B; Jovanovic P; Jelicic J; Martinovic VC; Jovanović J; Fekete MD; Čekerevac M; Bojanić N
Pol J Pathol; 2018; 69(2):136-142. PubMed ID: 30351860
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
35. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
[TBL] [Abstract][Full Text] [Related]
36. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
Barrans S; Crouch S; Smith A; Turner K; Owen R; Patmore R; Roman E; Jack A
J Clin Oncol; 2010 Jul; 28(20):3360-5. PubMed ID: 20498406
[TBL] [Abstract][Full Text] [Related]
37. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
38. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
[TBL] [Abstract][Full Text] [Related]
39. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
Kramer MH; Hermans J; Wijburg E; Philippo K; Geelen E; van Krieken JH; de Jong D; Maartense E; Schuuring E; Kluin PM
Blood; 1998 Nov; 92(9):3152-62. PubMed ID: 9787151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
